Skip to content
Open access

Risk-benefit assessment of oral anticoagulation in atrial fibrillation using virtual clinical trials

Nov 2026 · medRxiv · 0 citations
Medicine

TL;DR

It is provided the first virtual implementation of an ongoing rhythm-guided OAC trial, showing that pill-in-pocket OAC may lower bleeding risk compared to continuous OAC, highlighting the potential of virtual clinical trials to guide clinical trial design.

Abstract

Abstract Background: Oral anticoagulation (OAC) reduces stroke risk in patients with atrial fibrillation (AF), and screening can enable earlier AF detection and OAC initiation. However, the population-level trade-off between stroke prevention and OAC-related major bleeding for different types of AF and OAC therapy remains uncertain, and large randomized trials to resolve this are costly and time-consuming. Methods: A state-transition Markov-like model was developed to: 1) simulate the lifetime course of AF, stroke, major bleeding, and death in different virtual populations; 2) quantify benefits (stroke reduction) and harms (major bleeding) of systematic AF screening with screening-triggered OAC across CHA2DS2-VA scores; and 3) compare rhythm-guided, time-delimited ("pill-in-pocket") OAC with continuous OAC. Results: The model synthesized information from multiple clinical sources and reproduced stroke and bleeding incidence across clinical scenarios. At CHA?DS?-VA=2, long-term continuous rhythm monitoring (LT-CRM) with OAC lowered stroke risk (HR, 0.92 [95%CI, 0.88-0.96]) but raised bleeding risk (HR, 1.17 [95%CI, 1.07-1.27]) versus no screening. Time-to-benefit was shorter than time-to-harm for CHA?DS?-VA?4, but longer for CHA?DS?-VA=0. Pill-in-pocket OAC vs continuous OAC showed no difference in stroke/mortality (HR, 1.03, 95%CI [0.91-1.16]) but lower bleeding risk (HR, 0.81, 95%CI: 0.68-0.96]) in patients with elevated bleeding risk, but not at baseline. Sensitivity analyses revealed that the risk-benefit profiles of screening or pill-in-pocket OAC strategy further depend on OAC adherence and bleeding risks. Conclusions: Our model highlights a trade-off between stroke reduction and bleeding for systematic screening-initiated OAC, with net benefit for CHA?DS?-VA?4. We provide the first virtual implementation of an ongoing rhythm-guided OAC trial, showing that pill-in-pocket OAC may lower bleeding risk compared to continuous OAC, highlighting the potential of virtual clinical trials to guide clinical trial design.

Read PDF

Similar papers

Oct 2026

Stroke Risk-Based Anticoagulation After Atrial Fibrillation Ablation: ALONE-AF Post-Hoc Analysis.

BACKGROUND Discontinuation of oral anticoagulant (OAC) in patients without recurrent atrial arrhythmia after ablation for atrial fibrillation (AF) has been demonstrated to reduce composite outcomes of stroke, systemic embolism, and major bleeding compared with continued OAC. OBJECTIVE This study aimed to evaluate the...

Young-Shin Lee, J. Uhm, Junbeom Park et al. · 0 citations
Open access Oct 2026

Net clinical benefit of continued oral anticoagulants after successful AF ablation: a nationwide cohort study

Current guidelines recommend individual oral anticoagulant (OAC) decision after catheter ablation for atrial fibrillation (AF) based on stroke risk. However, recent randomized trials suggest that OAC discontinuation following successful ablation may be feasible in selected patients. Real-world evidence on the net...

Y. Lee, P.-S. Yang, E. Jang et al. · 0 citations
Nov 2026

Abstract 13527: Real World Evidence of the Consequences of Bleeding Events on Anticoagulant Use in Patients with Atrial Fibrillation in the United States

Background: Oral anticoagulation (OAC) reduces stroke risk in atrial fibrillation (AF), but major bleeding (MB) remains a concern. Current evidence on post-bleeding treatment patterns is limited. Question: How does bleeding influence OAC treatment patterns in the real-world? Methods: This retrospective s...

Mahmoud A. Hashim, E. O'Brien, A. Kang et al. · 0 citations
Open access Sep 2026

Optimal duration of anticoagulation after successful catheter ablation for atrial fibrillation: insights from recent randomized trials

The optimal duration of oral anticoagulation (OAC) after successful catheter ablation (CA) for atrial fibrillation (AF) remains controversial. Current guidelines recommend indefinite OAC based on stroke risk profiles, but long-term therapy adherence is suboptimal due to bleeding concerns. Recent randomized trials—ALONE...

Ming-Jie Lin, Bing Rong, Jing-Quan Zhong et al. · 0 citations
Review Nov 2026

Net Clinical Benefit of Continuing vs Discontinuing Anticoagulation After Atrial Fibrillation Ablation: Results from a 280,000-Patient Meta-Analysis.

Background Oral anticoagulation (OAC) in patients with atrial fibrillation (AF) reduces ischaemic stroke (IS), but increases bleeding, including intracranial haemorrhage (ICH). As catheter ablation reduces AF burden and IS risk, we evaluated the net clinical benefit (NCB) of continuing versus discontinuing OAC after AF...

S. Koolaji, Diana A. Gorog, J. Leader et al. · 0 citations
Review Open access Oct 2026

Atrial fibrillation in stroke patients: facts, numbers and current challenges

Atrial fibrillation (AF) is a leading, modifiable risk factor for ischaemic stroke, with 20–30% of stroke patients harbouring underlying AF. Management of AF, however, differs substantially depending on clinical context. In ischaemic stroke patients with pre-known AF, direct oral anticoagulants (DOACs) are the cornerst...

K. Wasser, Deborah Bochert, J. Leyhe et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.